Related Research Articles
Insulin resistance (IR) is a pathological condition in which cells either fail to respond normally to the hormone insulin or downregulate insulin receptors in response to hyperinsulinemia.
Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, fatigue and unexplained weight loss. Symptoms may also include increased hunger, having a sensation of pins and needles, and sores (wounds) that do not heal. Often symptoms come on slowly. Long-term complications from high blood sugar include heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. The sudden onset of hyperosmolar hyperglycemic state may occur; however, ketoacidosis is uncommon.
Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. It is sometimes used as an off-label adjunct to lessen the risk of metabolic syndrome in people who take antipsychotics. Metformin is not associated with weight gain and is taken by mouth.
Diabetes is a chronic disease in cats whereby either insufficient insulin response or insulin resistance leads to persistently high blood glucose concentrations. Diabetes affects up to 1 in 230 cats, and may be becoming increasingly common. Diabetes is less common in cats than in dogs. The condition is treatable, and if treated properly the cat can experience a normal life expectancy. In cats with type 2 diabetes, prompt effective treatment may lead to diabetic remission, in which the cat no longer needs injected insulin. Untreated, the condition leads to increasingly weak legs in cats and eventually to malnutrition, ketoacidosis and/or dehydration, and death.
Type 1 diabetes (T1D), formerly known as juvenile diabetes, is an autoimmune disease that originates when cells that make insulin are destroyed by the immune system. Insulin is a hormone required for the cells to use blood sugar for energy and it helps regulate glucose levels in the bloodstream. Before treatment this results in high blood sugar levels in the body. The common symptoms of this elevated blood sugar are frequent urination, increased thirst, increased hunger, weight loss, and other serious complications. Additional symptoms may include blurry vision, tiredness, and slow wound healing. Symptoms typically develop over a short period of time, often a matter of weeks if not months.
Slowly evolving immune-mediated diabetes, or latent autoimmune diabetes in adults (LADA), is a form of diabetes that exhibits clinical features similar to both type 1 diabetes (T1D) and type 2 diabetes (T2D), and is sometimes referred to as type 1.5 diabetes. It is an autoimmune form of diabetes, similar to T1D, but patients with LADA often show insulin resistance, similar to T2D, and share some risk factors for the disease with T2D. Studies have shown that LADA patients have certain types of antibodies against the insulin-producing cells, and that these cells stop producing insulin more slowly than in T1D patients. Since many people develop the disease later in life, it is often misdiagnosed as type 2 diabetes.
25-Hydroxyvitamin D 1-alpha-hydroxylase also known as calcidiol 1-monooxygenase or cytochrome p450 27B1 (CYP27B1) or simply 1-alpha-hydroxylase is a cytochrome P450 enzyme that in humans is encoded by the CYP27B1 gene.
Complications of diabetes are secondary diseases that are a result of elevated blood glucose levels that occur in diabetic patients. These complications can be divided into two types: acute and chronic. Acute complications are complications that develop rapidly and can be exemplified as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic acidosis (LA), and hypoglycemia. Chronic complications develop over time and are generally classified in two categories: microvascular and macrovascular. Microvascular complications include neuropathy, nephropathy, and retinopathy; while cardiovascular disease, stroke, and peripheral vascular disease are included in the macrovascular complications.
Derek LeRoith is a South African endocrinologist and Professor of Medicine and the current Chief of the Hilda and J. Lester Gabrilove, M.D. Division of Endocrinology, Diabetes and Bone Disease and Director of the Metabolism Institute of the Mount Sinai Medical Center in New York City. He is an international expert in insulin-like growth factor-1 (IGF-1).
Lente insulin was an intermediate duration insulin that is no longer used in humans. The onset of lente insulin is one to two hours after the dose is administered, and the peak effect is approximately 8 to 12 hours after administration, with some effects lasting over 24 hours.
Mark Atkinson is an American medical researcher best known for his contributions to research seeking to predict, prevent, and cure type 1 diabetes. He is the author of over 600 publications and is one of the world's most cited diabetes researchers.
Andrej Janež is a Slovenian diabetologist and diabetes researcher. Janež is the Head of Department of Endocrinology, Diabetes and Metabolic Disease at University Medical Centre Ljubljana, Assistant Professor for Internal Medicine at the Medical University Ljubljana, Chairman of the Advances in Diabetes and Insulin Therapy conference, member of the advisory board for peroral antidiabetic therapy in Servier Pharma, member for Slovenia in the Diabetes Education Study Group at European Association for the Study of Diabetes, and member of the European advisory board for continuous glucose monitoring system in development for Lifescan.
Bernhard Ludvik is a Specialist in Internal Medicine, board certified in Endocrinology and Metabolism. He is currently an Associate Professor of Medicine at the Medical University of Vienna. He serves as the Deputy Head of the Division of Endocrinology and Metabolism at the General Hospital Vienna.
Leonid Poretsky is a Russian-born American endocrinologist. His research interests include mechanisms of insulin action in the ovary, endocrinological aspects of AIDS, and clinical outcomes in diabetes. He has authored over 150 publications and has served on the National Institutes of Health's review committees and on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and other endocrine journals.
Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision. If left untreated, the disease can lead to various health complications, including disorders of the cardiovascular system, eye, kidney, and nerves. Untreated or poorly treated diabetes accounts for approximately 1.5 million deaths every year.
Shashank R. Joshi is an Indian endocrinologist, diabetologist and medical researcher, considered by many as one of the prominent practitioners of the trade in India. He was honoured by the Government of India, in 2014, by bestowing on him the Padma Shri, the fourth highest civilian award, for his services to the field of medicine. He is a part of the COVID-19 Task Force for the state of Maharashtra, India.
Stephanie Anne Amiel, Lady Alberti, is a British physician and academic, specialising in type 1 diabetes. Since 1995, she has been the R. D. Lawrence Professor of Diabetic Medicine at King's College London and a consultant at King's College Hospital.
Michael Roden is Professor and Chairman of Internal Medicine, Endocrinology and Metabolic Disorders at Heinrich Heine University Düsseldorf, Director of the Division of Endocrinology and Diabetology at the University Hospital of Düsseldorf and Spokesman for the Executive Board and Scientific Director of the German Diabetes Center, the Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf.
William V. Tamborlane has been Professor and Chief of Pediatric Endocrinology at Yale School of Medicine since 1986.
Brian M. Frier is a Scottish physician, diabetologist, clinical scientist, and an Honorary Professor of Diabetes at the University of Edinburgh. He is best known for his many scientific contributions to the pathophysiological understanding of hypoglycemia, a common adverse effect of insulin therapy in diabetic patients whose societal impact has deserved increasing media attention worldwide. His honors include the R.D. Lawrence Lecture of the British Diabetic Association in 1986, the Banting Memorial Lecture at Diabetes UK in 2009, the Camillo Golgi Prize and lecture at the 53rd annual EASD conference in 2017, and the Michael Somogyi Award from the Hungarian Diabetes Association in 2004. Frier is a science book author and editor, and a science journal Chief editor. He is also regarded as an authority on the field of driving and diabetes. In 2023, Frier was accorded Honorary Life Membership by the European Association of Diabetes.
References
- 1 2 3 "Scientific Advisory Board". Arecor Therapeutics. Retrieved 20 September 2021.
- ↑ "Thomas Pieber". European Association for the Study of Diabetes . Retrieved 20 September 2021.
- 1 2 "Faculty of the DK-MOLIN". Medical University of Graz . Retrieved 20 September 2021.
- ↑ "Somogyi Award". Hungarian Diabetes Association. Retrieved 20 September 2021.
- ↑ "Thomas Pieber". Google Scholar . Retrieved 18 April 2024.
| International | |
|---|---|
| National | |
| Academics | |
